Caveolin-1 prevents sustained angiotensin II-induced resistance artery constriction and obesity-induced high blood pressure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 5, 2015, Pages H376-H385

  Czikora, Istvan ^a   Feher, Attila ^a   Lucas, Rudolf ^a   Fulton, David J R ^a   Bagi, Zsolt ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Angiotensin receptor; Arteriole; Caveolae; Hypertension; Obesity; Trafficking

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BETA CYCLODEXTRIN; CAVEOLIN 1; CHOLESTEROL; FATTY ACID; GLUCOSE; ANGIOTENSIN 1 RECEPTOR; CAVEOLIN 2; PROTEIN BINDING; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CAVEOLA; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DIASTOLIC BLOOD PRESSURE; EXPERIMENTAL OBESITY; GENE SILENCING; HYPERTENSION; KNOCKOUT MOUSE; LIPID DIET; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; SENSITIZATION; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE CELL; AGONISTS; ANIMAL; ARTERY; CELL MEMBRANE; COMPLICATION; DRUG EFFECTS; GENETICS; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WISTAR RAT;

ANGIOTENSIN II; ANIMALS; ARTERIES; CAVEOLAE; CAVEOLIN 2; CELL MEMBRANE; HYPERTENSION; MALE; MUSCLE, SMOOTH, VASCULAR; OBESITY; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; VASCULAR RESISTANCE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84941989115     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00649.2014     Document Type: Article

References (43)

1. Ca channels and caveolin-rich domains. Br J Pharmacol 151: 332–340, 2007.
2. Anborgh PH, Seachrist JL, Dale LB, Ferguson SS. Receptor/betaarrestin complex formation and the differential trafficking and resensitization of beta2-adrenergic and angiotensin II type 1A receptors. Mol Endocrinol 14: 2040–2053, 2000.
3. Bagi Z. Mechanisms of coronary microvascular adaptation to obesity. Am J Physiol Regul Integr Comp Physiol 297: R556–R567, 2009.
4. 2 upregulates arteriolar constrictions to angiotensin II by increasing the functional availability of AT1 receptors. Am J Physiol Heart Circ Physiol 295: H835–H841, 2008.
5. Bagi Z, Erdei N, Toth A, Li W, Hintze TH, Koller A, Kaley G. Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 25: 1610–1616, 2005.
6. 1 receptors leads to sustained arterial constriction to angiotensin II in diabetes—role for Rho-kinase activation. Br J Pharmacol 163: 1059–1068, 2011.
7. Bagi Z, Koller A. Lack of NO-mediation of flow-dependent arteriolar dilation in diabetes is restored by sepiapterin. J Vasc Res 40: 47–57, 2003.
8. Cassuto J, Dou H, Czikora I, Szabo A, Patel VS, Kamath V, Belin de Chantemele E, Feher A, Romero MJ, Bagi Z. Peroxynitrite disrupts endothelial caveolae leading to eNOS uncoupling and diminished flowmediated dilation in coronary arterioles of diabetic patients. Diabetes 63: 1381–1393, 2014.
9. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 284: C457–C474, 2003.
10. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, Lisanti MP. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 285: C222–C235, 2003.
11. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 17: 16S–20S, 2004.
12. Desjardins F, Lobysheva I, Pelat M, Gallez B, Feron O, Dessy C, Balligand JL. Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. Cardiovasc Res 79: 527–536, 2008.
13. Erdei N, Toth A, Pasztor ET, Papp Z, Edes I, Koller A, Bagi Z. High-fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion. Am J Physiol Heart Circ Physiol 291: H2107–H2115, 2006.
14. Feher A, Rutkai I, Beleznai T, Ungvari Z, Csiszar A, Edes I, Bagi Z. Caveolin-1 limits the contribution of BKCa channel to EDHF-mediated arteriolar dilation: implications in diet-induced obesity. Cardiovasc Res 87: 732–739, 2010.
15. Graziani A, Bricko V, Carmignani M, Graier WF, Groschner K. Cholesterol- and caveolin-rich membrane domains are essential for phospholipase A2-dependent EDHF formation. Cardiovasc Res 64: 234–242, 2004.
16. Guo Z, Su W, Allen S, Pang H, Daugherty A, Smart E, Gong MC. COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res 67: 723–735, 2005.
17. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep 2: 139–147, 2000.
18. 2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 11: 1266–1277, 1997.
19. 1 angiotensin receptor internalization. Regul Pept 91: 29–44, 2000.
20. Ishizaka N, Griendling KK, Lassegue B, Alexander RW. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 32: 459–466, 1998.
21. Jebelovszki E, Kiraly C, Erdei N, Feher A, Pasztor ET, Rutkai I, Forster T, Edes I, Koller A, Bagi Z. High-fat diet-induced obesity leads to increased NO sensitivity of rat coronary arterioles: role of soluble guanylate cyclase activation. Am J Physiol Heart Circ Physiol 294: H2558–H2564, 2008.
22. Juul B, Aalkjaer C, Mulvany MJ. Responses of femoral resistance vessels to angiotensin in vitro. Eur J Pharmacol 135: 61–68, 1987.
23. Krieger MH, Di Lorenzo A, Teutsch C, Kauser K, Sessa WC. Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice. Lab Invest 90: 1573–1581, 2010.
24. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 273: 18677–18680, 1998.
25. Linder AE, Thakali KM, Thompson JM, Watts SW, Webb RC, Leite R. Methyl-beta-cyclodextrin prevents angiotensin II-induced tachyphylactic contractile responses in rat aorta. J Pharmacol Exp Ther 323: 78–84, 2007.
26. Lu T, Zhang DM, Wang XL, He T, Wang RX, Chai Q, Katusic ZS, Lee HC. Regulation of coronary arterial BK channels by caveolaemediated angiotensin II signaling in diabetes mellitus. Circ Res 106: 1164–1173, 2010.
27. Murata T, Lin MI, Huang Y, Yu J, Bauer PM, Giordano FJ, Sessa WC. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 204: 2373–2382, 2007.
28. Nishimatsu H, Suzuki E, Satonaka H, Takeda R, Omata M, Fujita T, Nagai R, Kitamura T, Hirata Y. Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol Heart Circ Physiol 288: H1770–H1776, 2005.
29. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 23: 888–892, 2000.
30. Pojoga LH, Romero JR, Yao TM, Loutraris P, Ricchiuti V, Coutinho P, Guo C, Lapointe N, Stone JR, Adler GK, Williams GH. Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-Larginine methyl ester and angiotensin II. Endocrinology 151: 1236–1246, 2010.
31. Pojoga LH, Yao TM, Opsasnick LA, Garza AE, Reslan OM, Adler GK, Williams GH, Khalil RA. Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice. J Pharmacol Exp Ther 348: 260–270, 2014.
32. Pojoga LH, Yao TM, Sinha S, Ross RL, Lin JC, Raffetto JD, Adler GK, Williams GH, Khalil RA. Effect of dietary sodium on vasoconstriction and eNOS-mediated vascular relaxation in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol 294: H1258–H1265, 2008.
33. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 45: 9–14, 2005.
34. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, Lisanti MP. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 277: 8635–8647, 2002.
35. Sorokin G, Grant NM, Egan BM, Lombard JH. Cyclooxygenase products do not modulate angiotensin II-induced contractions of human chorionic plate arteries. Am J Obstet Gynecol 167: 110–114, 1992.
36. Takayanagi T, Crawford KJ, Kobayashi T, Obama T, Tsuji T, Elliott KJ, Hashimoto T, Rizzo V, Eguchi S. Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase. Clin Sci (Lond) 126: 785–794, 2014.
37. Ullian ME, Linas SL. Role of receptor cycling in the regulation of angiotensin II surface receptor number and angiotensin II uptake in rat vascular smooth muscle cells. J Clin Invest 84: 840–846, 1989.
38. Ushio-Fukai M, Alexander RW. Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle. Hypertension 48: 797–803, 2006.
39. Vicaut E, Montalescot G, Hou X, Stucker O, Teisseire B. Arteriolar vasoconstriction and tachyphylaxis with intraarterial angiotensin II. Microvasc Res 37: 28–41, 1989.
40. Viswanad B, Srinivasan K, Kaul CL, Ramarao P. Effect of tempol on altered angiotensin II and acetylcholine-mediated vascular responses in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res 53: 209–215, 2006.
41. Williams TD, Chambers JB, Roberts LM, Henderson RP, Overton JM. Diet-induced obesity and cardiovascular regulation in C57BL/6J mice. Clin Exp Pharmacol Physiol 30: 769–778, 2003.
42. Wunderlich C, Schober K, Schmeisser A, Heerwagen C, Tausche AK, Steinbronn N, Brandt A, Kasper M, Schwencke C, Braun-Dullaeus RC, Strasser RH. The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. J Mol Cell Cardiol 44: 938–947, 2008.
43. Wyse BD, Prior IA, Qian H, Morrow IC, Nixon S, Muncke C, Kurzchalia TV, Thomas WG, Parton RG, Hancock JF. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem 278: 23738–23746, 2003.